GeoVax Labs (GOVX) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 17/876,682 to GeoVax, titled “Vaccinia Viral Vectors Encoding Chimeric Virus Like Particles.” The allowed claims add to GeoVax’s intellectual property protection related to its vector platform for expressing a tumor associated antigen, TAA, in virus-like particles, VLPs, from a recombinant Modified Vaccinia Ankara, MVA, viral vector, further demonstrating the GeoVax technical expertise.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOVX:
- WHO determines mpox upsurge still constitutes public health emergency
- GeoVax Labs announces interim data from Phase 2 trial of Vaccine technology
- GeoVax Labs Reports Improved Earnings and Strategic Progress
- GeoVax Labs reports Q3 EPS (91c), consensus ($1.48)
- Pinterest, Cisco upgraded: Wall Street’s top analyst calls